A crucial step: Locoregional control is a crucial step in the achievement o
f cancer cure. After mastectomy, locoregional irradiation (RT) dearly reduc
es the incidence of chest wall and nodal relapse, especially with initial l
esions measuring more than 5 an or with nodal involvement and/or large lymp
hatic or vascular emboli.
Clinical proof: Two recent randomized trials have confirmed the benefit of
weil-adapted locoregional irradiation. in the Danish trial, including preme
nopausal "high-risk" women treated by mastectomy and chemotherapy (CMF prot
ocol), RT reduced locoregional relapses from 32% to 9% (p < 0.01) and incre
ased the 10-year survival rate from 45% to 54% (p < 0.01). These results ar
e now confirmed in postmenopausal women with an increase in the 10-year sur
vival rate from 36% to 45% (p < 0.001). In the Canadian trial, locoregional
relapses decreased from 25% to 13% and the 10-year survival rate increased
from 56% to 65%. The meta-analysis published in 1995 by the EBCTCG showed
only a modest benefit due to locoregional irradiation in breast cancer. How
ever, when small trials and old trials started before 1970 were excluded be
cause of imperfect methodologies and inadequate irradiation techniques, the
benefit of "modern" radiotherapy appeared as significant in 7,840 patients
selected in this way.
In clinical practice: Thus, since locoregional irradiation can avoid some m
etastatic evolution developed only after "local" or "nodal" relapse, it mud
be integrated into a multidisciplinary strategy. Nevertheless, this treatm
ent must be safe. This can be achieved with new irradiation techniques incl
uding the definition of anatomical volumes and previsional dosimetry. The m
ost important point concerns the treatment of internal mammary nodes, espec
ially when previous chemotherapy including anthracyclines has been performe
d. The use of a direct field, with at least 40% of the dose delivered by el
ectrons in an alternating scheme is recommended to ensure veri, good protec
tion of the heart and lungs.